Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease

Alimentary Pharmacology & Therapeutics
G MonteleoneMarkus F Neurath

Abstract

In a phase 2 study, mongersen, an oral antisense oligonucleotide targeting Smad7, was effective in inducing clinical remission in approximately 60% of patients with active Crohn's disease (CD). In a post hoc analysis to evaluate those patient disease characteristics that may have influenced the efficacy and safety of mongersen therapy. Patients with steroid-dependent/resistant, active CD were randomised to mongersen 10, 40 or 160 mg/day or placebo for 2 weeks; patients were followed for 10 weeks. Clinical remission [Crohn's Disease Activity Index (CDAI) score <150] and clinical response (CDAI score reduction ≥100 points) were assessed at weeks 2, 4 and 12 for these subgroups: disease duration <5/≥5 years, human serum C-reactive protein (hsCRP) <3/≥3 mg/L, and CDAI at baseline ≤260/>260. Additional patient baseline and disease characteristics were explored. Clinical remission and response rates were significantly higher in patients receiving mongersen 40 and 160 mg/day but not 10 mg/day vs. placebo and independent of disease duration and hsCRP. Patients with baseline CDAI ≤260 had significantly higher remission rates with 40 and 160 mg/day. In patients with baseline CDAI >260, remission rates were statistically greater with 160 ...Continue Reading

References

Aug 24, 2001·The Journal of Clinical Investigation·G MonteleoneT T MacDonald
Aug 29, 2002·Gastroenterology·Mansour A ParsiAaron Brzezinski
Oct 3, 2002·The American Journal of Gastroenterology·Severine VermeireUNKNOWN Belgian Group of Infliximab Expanded Access Program in Crohn's Disease
Jun 26, 2003·Alimentary Pharmacology & Therapeutics·I D R ArnottJ Satsangi
Dec 3, 2010·Journal of Crohn's & Colitis·Gert Van AsscheUNKNOWN European Crohn's and Colitis Organisation (ECCO)
Jan 19, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Giovanni MonteleoneFrancesco Pallone
Mar 19, 2015·The New England Journal of Medicine·Giovanni MonteleoneFrancesco Pallone
May 8, 2015·Therapeutic Advances in Gastroenterology·Charles W RandallCarlo M Taboada
Jun 23, 2015·F1000prime Reports·Ray BoyapatiGwo-Tzer Ho

❮ Previous
Next ❯

Citations

Nov 11, 2016·Journal of Gastroenterology·Heyson Chi-Hey Chan, Siew Chien Ng
Mar 11, 2017·Expert Opinion on Therapeutic Targets·Tommaso GabbaniVito Annese
Apr 14, 2017·Current Opinion in Gastroenterology·Heitor S P de Souza
Mar 23, 2017·Molecular Therapy. Nucleic Acids·Yuanyu Huang
Dec 6, 2016·Trends in Pharmacological Sciences·Mehmet CoskunOle Haagen Nielsen
Oct 21, 2017·Therapeutic Advances in Gastroenterology·Marcel Vetter, Markus F Neurath
Oct 10, 2018·Current Opinion in Allergy and Clinical Immunology·Vritika Batura, Aleixo M Muise
Nov 20, 2016·Gut·Pablo OliveraLaurent Peyrin-Biroulet
Jul 29, 2016·World Journal of Gastroenterology : WJG·Dániel SzűcsGábor Veres
Dec 25, 2017·Digestive Diseases and Sciences·Paolo GiuffridaAntonio Di Sabatino
Feb 17, 2018·Expert Opinion on Investigational Drugs·Remi LabetoulleXavier Roblin
Oct 27, 2016·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·Ho Jae LeeKi Baik Hahm
Apr 20, 2018·Alimentary Pharmacology & Therapeutics·J R WhiteG W Moran
Aug 22, 2017·Frontiers in Medicine·Renata CurciarelloThomas T MacDonald
May 6, 2017·Expert Review of Clinical Pharmacology·Shannon Chang, Stephen Hanauer
Aug 24, 2018·Journal of Crohn's & Colitis·Palak J Trivedi, David H Adams
Apr 20, 2021·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Irene MarafiniGiovanni Monteleone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

© 2022 Meta ULC. All rights reserved